Patents
OxyBridge™ is protected by granted patents in the United States, Europe and Australia, with further applications pending. Each is listed below by publication number, jurisdiction and status, and can be looked up in the issuing office’s own register.
Granted
| Patent | Jurisdiction | Title | Granted |
|---|---|---|---|
| US 11,504,417 B2United States · 2022 | United States | Blood substitutes comprising hemoglobin and methods of making | 2022 |
| US 12,582,703 B2United States · 2026 | United States | Blood substitutes comprising hemoglobin and methods of making | 2026 |
| AU 2018304174Australia · 23 October 2025 | Australia | Blood substitutes comprising hemoglobin and methods of making | 23 October 2025 |
| EP 4167961Europe · 29 April 2026Registered as a Unitary Patent across 18 member states. | Europe | Compositions and methods for treating hemorrhagic shock | 29 April 2026 |
Pending
| Application | Jurisdiction | Title | Status |
|---|---|---|---|
| AU 2025230792Australia · Published 2 October 2025 | Australia | Oxygenation media for ex-vivo preservation of organs and tissues | Published 2 October 2025 |
| AU 2025248707Australia · Published 30 October 2025 | Australia | Blood substitutes comprising hemoglobin and methods of making | Published 30 October 2025 |
Applicant of record on all six is Virtech Bio Inc. Inventor throughout is W. Richard Light, with Joseph Tucker named on the US and Australian blood substitute filings. Records verified against the USPTO, IP Australia and the EPO registers on 1 September 2026.